The Octapharma Production System (OPS) initiative, launched in 2020, ensures our production facilities remain at the cutting edge of our industry. Since the inception of OPS, we’ve transformed numerous value stream areas within our production site, boosting efficiency. Our continuous pursuit to refine workflows empowers our team to focus on what truly matters —meeting the needs of our patients. Discover how OPS has helped to create a more structured work environment, establish new approaches, stabilize production, and enhance predictability across our production sites here: https://bit.ly/3LsyUP9
Octapharma
Arzneimittelherstellung
Lachen, Switzerland 50.211 Follower:innen
Our passion drives us to provide new health solutions advancing human life
Info
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml
- Website
-
http://www.octapharma.com
Externer Link zu Octapharma
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Lachen, Switzerland
- Art
- Privatunternehmen
- Gegründet
- 1983
- Spezialgebiete
- Plasma Fractionation, Haematology, Immunotherapy und Critical Care
Orte
Beschäftigte von Octapharma
Updates
-
Indonesia sprawls over 17,000 islands, and many patients live far from city hospitals. Additionally, there is a lack of understanding about haemophilia among patients, their relatives, and even some healthcare providers. Fortunately, Deni’s haemophilia was diagnosed early, but many other haemophilia patients in Indonesia remain undiagnosed or receive inadequate care. Deni now shares his story to raise awareness of this life-changing disease. Read the article here: https://bit.ly/441xrb2
-
-
What is the most effective way to keep growing and developing? According to Ludovic Jouanolou, the secret lies in nurturing curiosity and a desire to learn throughout your career. Discover his remarkable career journey from a Production Trainee to Head of Quality Assurance, Systems & Qualified Person at Octapharma Lingolsheim here: https://bit.ly/3VYrNDc
-
-
Critical medical conditions in combination with life-threatening bleeding in trauma or surgery require effective interventions such as carefully managed coagulation therapy. Yet, evidence and accepted standards in this field remain limited, leading to variable patient outcomes. To bridge this treatment gap, Octapharma collaborates with leading medical centres across the USA and globally to enhance the understanding and implementation of personalised approaches to manage bleeding. Explore our efforts in bleeding management and critical care here: https://bit.ly/48QLukI
-
-
Data on the use of IVIG in Chronic Inflammatory Demyelinating Polyneuropathy (#CIDP) will be presented at the Peripheral Nerve Society (PNS) 2024 Annual Meeting from June 22 to 25, 2024. Attending on site in Montreal? Visit us at exhibit table #25! Learn more: https://bit.ly/4cqXs6J For HCPs only. #PNS2024
-
-
Next week at #ISTH2024, Craig Kessler, Wolfgang Miesbach, Robert F. Sidonio Jr., Ana Boban, and Jill Johnsen will examine the critical role of prophylaxis in severe von Willebrand disease. Join our Under the Spotlight symposium on Monday, June 24 at 12:15 ICT in Bangkok or virtually on One Source: https://bit.ly/3x79za3 The event is for HCPs only.
-
Plasma in our bodies helps protect us from infection and blood disorders. It also plays a vital role in coagulation. In their many medical applications, plasma-derived therapies have helped thousands of people with life-threatening conditions. Plasma is a potential lifesaver. That’s why, at Octapharma, our plasma donors are as important to us as our patients. Karin began donating regularly at Octapharma Plasma in 2010. Today, she ranks among the top active donors with more than 1,400 donations. Read her story here: https://bit.ly/3VjEjg4
-
-
During the #ISTH2024 congress next week, we discuss the latest clinical and scientific breakthroughs in haemophilia A care. Join Guy Young, Carmen Escuriola Ettinsghausen, Viola Vogel, Yesim Dargaud, and Antonia Follenzi at our Under the Spotlight symposium on Sunday, June 23 at 12:15 ICT in Bangkok or watch the session live on One Source: https://bit.ly/3x79za3 The event is for HCPs only.
-
Join us at #ISTH2024 to learn about the critical role of prophylaxis in severe von Willebrand Disease (#VWD) and the treatment of heavy menstrual bleeding. Our Under the Spotlight symposium “Next-Level Insights on Prophylaxis in VWD – Are you Addressing your Patients’ Needs?” will be held on Monday, June 24 at 12:15 ICT in Bangkok and virtually via One Source. Sign up for the live stream here: https://bit.ly/3x79za3 The event is for healthcare professionals only.
-
The most recent developments from Octapharma’s Haematology portfolio will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) on June 22–26, 2024, in Bangkok, Thailand. The data will be featured in seven oral presentations, two poster presentations and two Supported Symposia during this key international meeting. Read the press release here: https://bit.ly/4efNhU3 #ISTH2024
-